Cargando…
Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis
Autores principales: | Cuenca, Isabel, Alameda, Daniel, Sanchez-Vega, Beatriz, Gomez-Sanchez, David, Alignani, Diego, Lasa, Marta, Onecha, Esther, Lecumberri, Ramon, Prosper, Felipe, Ocio, Enrique M., González, Maria Esther, García de Coca, Alfonso, De La Rubia, Javier, Gironella, Mercedes, Palomera, Luis, Oriol, Albert, Casanova, Maria, Cabañas, Valentin, Taboada, Francisco, Pérez-Montaña, Albert, De Arriba, Felipe, Puig, Noemi, Carreño-Tarragona, Gonzalo, Barrio, Santiago, Enrique de la Puerta, Jose, Ramirez-Payer, Angel, Krsnik, Isabel, Bargay, Juan Jose, Lahuerta, Juan Jose, Mateos, Maria-Victoria, San-Miguel, Jesus F., Paiva, Bruno, Martinez-Lopez, Joaquin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7787969/ https://www.ncbi.nlm.nih.gov/pubmed/32203144 http://dx.doi.org/10.1038/s41375-020-0800-6 |
Ejemplares similares
-
Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature
por: Rodríguez-Otero, Paula, et al.
Publicado: (2019) -
Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial
por: Puig, Noemí, et al.
Publicado: (2020) -
Randomized phase II study of weekly carfilzomib 70 mg/m(2) and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients
por: Puertas, Borja, et al.
Publicado: (2023) -
Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma
por: Puig, Noemí, et al.
Publicado: (2022) -
Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations()
por: Lopez, Aurelio, et al.
Publicado: (2015)